ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson's disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist (SSIA), targeting 5-HT2A receptors. The Company's Pimavanserin is a chemical entity, which has completed Phase III development, and is indicated for the treatment of Parkinson's disease psychosis. NUPLAZID (pimavanserin) is a selective serotonin inverse agonist preferentially targeting the 5-HT2A receptor, a key serotonin receptor that plays a role in psychosis. Through this mechanism, NUPLAZID has demonstrated efficacy in Parkinson's disease psychosis in its Phase III pivotal trial and avoids the side effects of existing antipsychotics.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACAD
  • CUSIP:
Key Metrics:
  • Previous Close: $39.56
  • 50 Day Moving Average: $34.88
  • 200 Day Moving Average: $30.45
  • 52-Week Range: $121,113,000.00 - $17.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.20
  • P/E Growth: -1.11
  • Market Cap: $4.71B
  • Outstanding Shares: 121,113,000
  • Beta: 3.94
Profitability:
  • Net Margins: -4,427.79%
  • Return on Equity: -58.46%
  • Return on Assets: -54.70%
Debt:
  • Current Ratio: 15.42%
  • Quick Ratio: 15.31%
Additional Links:
Companies Related to ACADIA Pharmaceuticals:

Analyst Ratings

Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (?)
Ratings Breakdown: 4 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.69)
Consensus Price Target: $41.25 (6.10% upside)

Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Show:
DateFirmActionRatingPrice TargetDetails
2/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$44.00View Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$49.00 -> $48.00View Rating Details
1/24/2017Needham & Company LLCReiterated RatingBuy$49.00View Rating Details
1/24/2017Cowen and CompanyReiterated RatingOutperform$42.00View Rating Details
1/11/2017J P Morgan Chase & CoReiterated RatingBuyView Rating Details
12/28/2016Leerink SwannReiterated RatingMarket Perform$29.00View Rating Details
12/23/2016HC WainwrightReiterated RatingBuy$60.00View Rating Details
11/11/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$28.00View Rating Details
11/8/2016Bank of America CorpUpgradeNeutral -> Buy$35.00View Rating Details
10/19/2016Roth CapitalReiterated RatingNeutral$25.00View Rating Details
8/25/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
8/10/2016JMP SecuritiesReiterated RatingBuy$45.00View Rating Details
8/5/2016AegisDowngradeBuy -> Hold$54.00 -> $41.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($0.65)$9.05 millionN/AView Earnings Details
11/7/2016Q316($0.56)($0.61)$2.90 million$5.30 millionViewListenView Earnings Details
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)ViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)ViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)ViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Current Year EPS Consensus Estimate: $-2.34 EPS
Next Year EPS Consensus Estimate: $-2.26 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.44)($0.44)($0.44)
Q2 20161($0.46)($0.46)($0.46)
Q3 20162($0.53)($0.52)($0.53)
Q4 20162($0.68)($0.54)($0.61)
Q1 20171($0.53)($0.53)($0.53)
Q2 20171($0.48)($0.48)($0.48)
Q3 20171($0.44)($0.44)($0.44)
Q4 20171($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Ownership Percentage: 21.65%
Institutional Ownership Percentage: 98.25%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Terrence O. MooreEVPSell157,540$39.77$6,265,365.80View SEC Filing  
12/27/2016Glenn BaityEVPSell9,800$30.46$298,508.00View SEC Filing  
12/20/2016Glenn BaityEVPSell10,000$30.00$300,000.00View SEC Filing  
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.00View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.00View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.00View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateHeadline
News IconACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Mean Price Target At $41.375 (NASDAQ:ACAD)
mundoaguaysaneamiento.net - February 25 at 8:17 PM
News IconWhat's Happening To These Stocks? – PBF Energy Inc. (PBF), ACADIA Pharmaceuticals Inc. (ACAD) - Post Analyst (NASDAQ:ACAD)
postanalyst.com - February 25 at 3:16 PM
investopedia.com logoWill Acadia Beat Estimates Again? Maybe. (NASDAQ:ACAD)
www.investopedia.com - February 24 at 8:17 PM
News IconAre Analysts Optimistic About Where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Heading? - Winfield Review (NASDAQ:ACAD)
winfieldreview.com - February 24 at 3:15 PM
News IconA Keen Look At The Chart For ACADIA Pharmaceuticals Inc. (ACAD) - NY Stock News (NASDAQ:ACAD)
nystocknews.com - February 24 at 3:15 PM
News IconDrilling Down Into the Charts for ACADIA Pharmaceuticals Inc. (ACAD) - The USA Commerce (NASDAQ:ACAD)
theusacommerce.com - February 24 at 3:15 PM
News IconTraders Secrets on ACADIA Pharmaceuticals Inc. (ACAD), VeriFone Systems, Inc. (PAY) - StockNewsJournal (NASDAQ:ACAD)
stocknewsjournal.com - February 24 at 3:15 PM
News IconStock Price of ACADIA Pharmaceuticals Inc. (ACAD) Increases 5.9% - Highland Mirror (NASDAQ:ACAD)
www.highlandmirror.com - February 23 at 3:18 PM
News IconAnalyst's Indicator Review for Packaging Corporation of America (PKG), ACADIA Pharmaceuticals Inc. (ACAD) - The USA Commerce (NASDAQ:ACAD)
theusacommerce.com - February 23 at 3:18 PM
News IconChart Watch: Following Indicators on Shares of ACADIA Pharmaceuticals Inc (ACAD) - BVN (NASDAQ:ACAD)
bvnewsjournal.com - February 22 at 8:18 PM
News IconStocks To Look Out For – Immunomedics, Inc. (NASDAQ:IMMU), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Wall Street Times (press release) (NASDAQ:ACAD)
www.wallstreetnews24.com - February 22 at 3:18 PM
nasdaq.com logoFirst Week of April 21st Options Trading For Acadia Pharmaceuticals - Nasdaq (NASDAQ:ACAD)
www.nasdaq.com - February 22 at 3:18 PM
News IconTrading Radar: Zooming in on Shares of ACADIA Pharmaceuticals Inc (ACAD) - SKV News (NASDAQ:ACAD)
skvnews.com - February 21 at 3:34 PM
prnewswire.com logoBiotech Stocks under Scanner -- ACADIA Pharma, Clovis Oncology, Galena Biopharma, and Northwest Biotherapeutics - PR Newswire (press release) (NASDAQ:ACAD)
www.prnewswire.com - February 21 at 3:34 PM
finance.yahoo.com logoACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017 (NASDAQ:ACAD)
finance.yahoo.com - February 21 at 3:34 PM
News IconEarnings Take Center Stage; Analysts Weighing in on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Aiken Advocate (NASDAQ:ACAD)
aikenadvocate.com - February 21 at 5:32 AM
News IconIs It Time to go for Valley National Bancorp (VLY), ACADIA Pharmaceuticals (ACAD)? - StockNewsJournal (NASDAQ:ACAD)
www.stocknewsjournal.com - February 21 at 5:32 AM
News IconAnalyst's Indicator Review for Teradata Corporation (TDC), ACADIA Pharmaceuticals Inc. (ACAD) - The USA Commerce (NASDAQ:ACAD)
www.theusacommerce.com - February 18 at 3:16 PM
News IconACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price At $41.375 - Transcript Daily (NASDAQ:ACAD)
transcriptdaily.com - February 18 at 3:16 PM
News IconAcadia Pharmaceuticals Inc ACAD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ACAD)
www.bioportfolio.com - February 16 at 8:20 PM
News IconLLC Decreases Position in ACADIA Pharmaceuticals Inc. (ACAD) (NASDAQ:ACAD)
interiordesignfuture.com - February 16 at 8:20 PM
News IconLLC Decreases Position in ACADIA Pharmaceuticals Inc. (ACAD) (NASDAQ:ACAD)
interiordesignfuture.com - February 16 at 8:20 PM
News IconACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Current Opinions and Recommendations (NASDAQ:ACAD)
cloudhostinghq.net - February 16 at 8:20 PM
News IconACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Current Opinions and Recommendations (NASDAQ:ACAD)
giftedviz.com - February 16 at 8:20 PM
News IconACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price Means Stock Is Worth $42.25 (NASDAQ:ACAD)
naijaoversabi.com - February 16 at 8:20 PM
News IconACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price Means Stock Is Worth $42.25 (NASDAQ:ACAD)
naijaoversabi.com - February 16 at 8:20 PM
News IconAnalyst's Predictions on Two Harbors Investment Corp. (TWO), ACADIA Pharmaceuticals Inc. (ACAD) - StockNewsJournal (NASDAQ:ACAD)
stocknewsjournal.com - February 16 at 3:19 PM
investopedia.com logoAcadia Pharmaceuticals Surge Higher Is More Than M&A Rumors (NASDAQ:ACAD)
www.investopedia.com - February 16 at 3:19 PM
News IconWhy Investors remained confident on ACADIA Pharmaceuticals Inc. (ACAD), Cornerstone OnDemand, Inc. (CSOD)? - StockNewsJournal (NASDAQ:ACAD)
stocknewsjournal.com - February 16 at 6:16 AM
gurufocus.com logoWeatherbie Capital, Llc Buys Portola Pharmaceuticals, Everbridge, ACADIA Pharmaceuticals, Sells FleetMatics Group ... - GuruFocus.com (NASDAQ:ACAD)
www.gurufocus.com - February 16 at 6:16 AM
fool.com logoCaution: Acadia Pharmaceuticals Is Overvalued (NASDAQ:ACAD)
www.fool.com - February 16 at 6:16 AM
finance.yahoo.com logoPrice Bump From M&A Rumors Earns Acadia A Vetr Downgrade (NASDAQ:ACAD)
finance.yahoo.com - February 16 at 6:16 AM
News IconTechnical Checkup on Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Baldwin Journal (NASDAQ:ACAD)
baldwinjournal.com - February 14 at 3:32 PM
News IconThe Technical Facts on ACADIA Pharmaceuticals Inc. (ACAD) - The USA Commerce (NASDAQ:ACAD)
theusacommerce.com - February 14 at 3:32 PM
fool.com logoCaution: Acadia Pharmaceuticals Is Overvalued -- The Motley Fool - Motley Fool (NASDAQ:ACAD)
www.fool.com - February 14 at 3:31 PM
News IconEarnings According to Analysts for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Aiken Advocate (NASDAQ:ACAD)
aikenadvocate.com - February 13 at 8:22 PM
News IconACADIA Pharmaceuticals Inc. (ACAD), Tempur Sealy International, Inc. (TPX) Stock Eyes Ahead of Earnings - The USA Commerce (NASDAQ:ACAD)
theusacommerce.com - February 13 at 3:21 PM
News IconShares of ACADIA Pharmaceuticals Inc. (ACAD) Sees Large Inflow of Net Money Flow - Highland Mirror (NASDAQ:ACAD)
www.highlandmirror.com - February 13 at 3:21 PM
fool.com logoA Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease (NASDAQ:ACAD)
www.fool.com - February 12 at 3:18 PM
News IconACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Price Target At $41.375 - Transcript Daily (NASDAQ:ACAD)
transcriptdaily.com - February 10 at 8:23 PM
News IconTraders Secrets on ACADIA Pharmaceuticals Inc. (ACAD), Cadence Design Systems, Inc. (CDNS) - StockNewsJournal (NASDAQ:ACAD)
stocknewsjournal.com - February 10 at 3:18 PM
News IconForward Earnings Estimate of ACADIA Pharmaceuticals Inc.(ACAD) - Highland Mirror (NASDAQ:ACAD)
www.highlandmirror.com - February 10 at 3:18 PM
News IconAnalyst's Indicator Review for Gulfport Energy Corp. (GPOR), ACADIA Pharmaceuticals Inc. (ACAD) - The USA Commerce (NASDAQ:ACAD)
theusacommerce.com - February 9 at 3:16 PM
News IconHow Does ACADIA Pharmaceuticals Inc. (ACAD) Stack Up Right Now? - StockNewsJournal (NASDAQ:ACAD)
stocknewsjournal.com - February 9 at 3:16 PM
News IconThe Technical Case for and Against ACADIA Pharmaceuticals Inc. (ACAD) - The USA Commerce (NASDAQ:ACAD)
www.theusacommerce.com - February 8 at 8:35 PM
News IconLookout for Price Target? Finisar Corporation (FNSR), ACADIA Pharmaceuticals Inc. (ACAD) - StockNewsJournal (NASDAQ:ACAD)
stocknewsjournal.com - February 8 at 3:20 PM
News IconNational Planning Corp Has $1067000 Position in ACADIA Pharmaceuticals Inc. (ACAD) (NASDAQ:ACAD)
brassale.net - February 8 at 1:21 AM
News IconLadenburg Thalmann Assumes ACADIA Pharmaceuticals to Buy with Price Target $48 (NASDAQ:ACAD)
mlbinjurynews.com - February 8 at 1:21 AM
marketexclusive.com logoAnalyst Activity – Piper Jaffray Companies Reiterates Overweight on ACADIA Pharmaceuticals (NASDAQ:ACAD) (NASDAQ:ACAD)
marketexclusive.com - February 8 at 1:21 AM
smarteranalyst.com logoPiper Jaffary Previews ACADIA Pharmaceuticals Inc.’s (ACAD) Upcoming Earnings (NASDAQ:ACAD)
www.smarteranalyst.com - February 8 at 1:21 AM

Social

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2017?

13 analysts have issued 12 month price targets for ACADIA Pharmaceuticals' stock. Their predictions range from $25.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $41.25 in the next twelve months.

When will ACADIA Pharmaceuticals announce their earnings?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Franklin Resources Inc. (3.49%), State Street Corp (2.77%), Fred Alger Management Inc. (1.63%), Palo Alto Investors LLC (1.26%) and Frontier Capital Management Co. LLC (0.31%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore.

Who sold ACADIA Pharmaceuticals stock? Who is selling ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Van ECK Associates Corp, Frontier Capital Management Co. LLC, Dimensional Fund Advisors LP, Fred Alger Management Inc., Fiera Capital Corp, Allianz Asset Management AG, United Capital Financial Advisers LLC and ING Groep NV. Company insiders that have sold ACADIA Pharmaceuticals stock in the last year include Glenn Baity, Leslie L Iversen and Terrence O Moore.

Who bought ACADIA Pharmaceuticals stock? Who is buying ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Handelsbanken Fonder AB, FMR LLC, Palo Alto Investors LLC, Franklin Resources Inc., Acuta Capital Partners LLC, Turner Investments LLC and Highland Capital Management LP. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Edmund Harrigan and LP 14159.

How do I buy ACADIA Pharmaceuticals stock?

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ACADIA Pharmaceuticals stock cost?

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $38.88.

ACADIA Pharmaceuticals (NASDAQ:ACAD) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Earnings History Chart

Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Dividend History Chart

Dividend Payments by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Last Updated on 2/27/2017 by MarketBeat.com Staff